David Olansky, MD
MOHS-Micrographic Surgery · Atlanta, GANPI 1689641227
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,000 of the $12,842 with a category attached, or 62.3%. Barco, Inc. accounts for 62.3% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $8,510 and has fallen 96.6% since, to $292 in 2024.
Across 136 payments — averaging $94.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Barco, Inc.$8K
- Merz North America, Inc.$2K
- AbbVie$425
- LEO Pharma Inc.$284
- Lilly USA, LLC$188
- Johnson & Johnson$159
- plus $1K from 26 others
What the payments were for
- Speaking & faculty fees$8,00062%
- Food & beverage$4,84238%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Barco, Inc. | 1 | $8,000 |
| Merz North America, Inc. | 8 | $2,381 |
| AbbVie | 20 | $425 |
| LEO Pharma Inc. | 14 | $284 |
| Lilly USA, LLC | 10 | $188 |
| Johnson & Johnson | 8 | $159 |
| Sun Pharmaceutical Industries Inc. | 7 | $138 |
| Dermavant Sciences, Inc. | 7 | $128 |
| Amgen | 5 | $126 |
| Pfizer | 8 | $122 |
| Arcutis Biotherapeutics, Inc. | 6 | $108 |
| Regeneron Healthcare Solutions, Inc. | 4 | $105 |
| Genentech USA, Inc. | 5 | $86 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 5 | $86 |
| Incyte Corporation | 3 | $68 |
| Boehringer Ingelheim | 3 | $56 |
| Galderma Laboratories, L.p. | 3 | $55 |
| Sanofi | 2 | $38 |
| UCB, Inc. | 2 | $36 |
| Almirall LLC | 2 | $30 |
| Prugen, Inc. Pharmaceuticals | 2 | $25 |
| Novartis | 1 | $25 |
| EPI Health, LLC | 1 | $23 |
| Organogenesis Inc. | 1 | $22 |
| Biofrontera Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Stemline Therapeutics Inc. | 1 | $14 |
| Merck | 1 | $13 |
| Dermira, Inc. | 1 | $13 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Skyrizi$105
How this compares
$12,842 in reported general payments places this provider in the 85th percentile of 40 mohs-micrographic surgery providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 24 | $1,219 |
| Metronidazole | 17 | $988 |
| Imiquimod | 17 | $891 |
| Triamcinolone Acetonide | 31 | $380 |
| Doxycycline Hyclate | 15 | $257 |
| Clobetasol Propionate | 11 | $189 |
| Hydrocortisone | 14 | $137 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Atlanta
- Diamondis PapadopoulosAtlanta$9K
- Melissa BabcockAtlanta$3K
- Humza IlyasAtlanta$3K
- Julia NeckmanAtlanta$3K
- Valerie TruongAtlanta$2K
- Mary Alice MinaAtlanta$533
- Amy KimAtlanta$430
- Mark BaucomAtlanta$146
- Wallace NozileStockbridge$213K
- Brandon BurrowayDuluth$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.